Clal Biotechnology reported ILS5.15M in Operating Expenses for its fiscal quarter ending in December of 2022.


Operating Expenses Change Date
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.69M 736K Jun/2025
Life Technologies USD 20.31M 4.49M Jun/2025
RedHill Biopharma USD 5.51M 1.08M Jun/2024